Try our mobile app

Switch to company model in classical logic    *

General information

Country: BRITAIN

Sector: Biotechnology

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. In addition, the company`s programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
Website: immunocore.com



Growth: Good revenue growth rate >200%, there is acceleration compared to average historical growth rates 98.8%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, -108.7%. On average the margin is improving steadily. Gross margin is high, +99.9%. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 60% of quarters (showing a gain of +$9.83 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -22.3% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 15.6% higher than minimum and 60.9% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 5.2x by EV / Sales multiple , the company can be 60.5% overvalued

Insiders: For the last 3 months insiders bought company shares on $24.0 mln (1.839% of cap.)

Key Financials (Download financials)

Ticker: IMCR
Share price, USD:  (+2.8%)29.43
year average price 36.66  


year start price 62.21 2024-04-04

max close price 63.50 2024-04-05

min close price 27.93 2024-12-18

current price 29.43 2025-04-03
Common stocks: 43 897 101

Dividend Yield:  0.0%
EV / Sales: 13.1x
Margin (EBITDA LTM / Revenue): -108.7%
Fundamental value created in LTM:
Market Cap ($m): 1 292
Net Debt ($m): 66
EV (Enterprise Value): 1 358
Price to Book: 3.4x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2025-03-10globenewswire.com

Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025

2025-02-27seekingalpha.com

Immunocore: A Commercial Biotech Nearing Its Pivotal Break-Even Point

2025-02-19globenewswire.com

Immunocore to report fourth quarter and full year 2024 financial results and host call on February 26, 2025

2025-02-17zacks.com

Immunocore Gears Up to Report Q4 Earnings: Is a Beat in Store?

2025-01-13zacks.com

Wall Street Analysts Believe Immunocore (IMCR) Could Rally 113.13%: Here's is How to Trade

2025-01-10globenewswire.com

Immunocore announces strategic priorities at 43rd Annual J.P. Morgan Healthcare Conference

2024-12-12zacks.com

All You Need to Know About Immunocore (IMCR) Rating Upgrade to Strong Buy

2024-12-12zacks.com

New Strong Buy Stocks for December 12th

2024-12-03globenewswire.com

Immunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma

2024-11-28zacks.com

Does Immunocore (IMCR) Have the Potential to Rally 112.82% as Wall Street Analysts Expect?
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol IMCR IMCR IMCR IMCR IMCR IMCR IMCR IMCR IMCR
reportedCurrency USD USD USD USD GBP GBP GBP GBP GBP
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-06 2024-08-08 2024-05-08 2023-11-07 2023-11-07 2023-08-10 2023-03-01 2022-12-31 2022-11-18
acceptedDate 2024-11-06 07:00:49 2024-08-08 07:06:42 2024-05-08 07:00:48 2023-11-07 07:09:18 2023-11-07 07:09:18 2023-08-10 08:28:14 2023-03-01 08:06:28 2022-12-30 19:00:00 2022-11-18 16:17:11
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
revenue 80M 75M 71M 106M 51M 48M 45M 48M 41M
costOfRevenue 448 000 2M 246 000 -247 000 220 000 886 000 178 000 109 000 63 000
grossProfit 80M 74M 70M 106M 51M 47M 44M 48M 41M
grossProfitRatio 0.994 0.977 0.997 1.002 0.996 0.981 0.996 0.998 0.998
researchAndDevelopmentExpenses 53M 51M 57M 75M 32M 29M 28M 27M 23M
generalAndAdministrativeExpenses 24M 26M 0 47M 11M 36M 0 0 18M
sellingAndMarketingExpenses 12M 13M 0 17M 0 0 0 0 7M
sellingGeneralAndAdministrativeExpenses 36M 39M 39M 57M 11M 36M 33M 43M 26M
otherExpenses 0 4M -190 000 0 0 0 0 -2000 964 000
operatingExpenses 88M 90M 97M 132M 43M 65M 62M 70M 50M
costAndExpenses 89M 91M 97M 132M 43M 66M 62M 70M 50M
interestIncome 6M 6M 8M 8M 4M 3M 3M 2M 597 000
interestExpense 4M 4M 3M 337 000 2M 2M 2M 3M 2M
depreciationAndAmortization 1M 992 000 1M 121 000 1M 1M 4M 2M 2M
ebitda 11M -16M -17M -19M 14M -13M -14M -20M -7M
ebitdaratio 0.136 -0.065 -0.247 -0.177 0.273 -0.276 -0.304 -0.414 -0.168
operatingIncome -9M -16M -26M -26M -699 000 -16M -17M -22M -9M
operatingIncomeRatio -0.106 -0.212 -0.376 -0.244 -0.014 -0.33 -0.39 -0.465 -0.219
totalOtherIncomeExpensesNet 15M 6M -3M -14M -9M 2M 926 000 -748 000 14M
incomeBeforeTax 6M -10M -24M -32M 2M -14M -16M -23M 5M
incomeBeforeTaxRatio 0.076 -0.134 -0.342 -0.305 0.034 -0.292 -0.37 -0.48 0.121
incomeTaxExpense -3M 1M 357 000 -6M -144 000 151 000 236 000 2M -1M
netIncome 9M -12M -24M -26M 2M -14M -17M -25M 6M
netIncomeRatio 0.109 -0.154 -0.347 -0.25 0.037 -0.295 -0.375 -0.524 0.151
eps 0.17 -0.23 -0.49 -0.54 0.04 -0.29 -0.35 -0.54 0.13
epsdiluted 0.17 -0.23 -0.49 -0.54 0.04 -0.29 -0.35 -0.54 0.12
weightedAverageShsOut 50M 50M 50M 49M 54M 49M 48M 47M 47M
weightedAverageShsOutDil 53M 50M 50M 49M 54M 49M 48M 47M 51M
link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol IMCR IMCR IMCR IMCR IMCR IMCR IMCR IMCR IMCR
reportedCurrency USD USD USD USD GBP GBP USD GBP GBP
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-06 2024-08-08 2024-05-08 2023-11-07 2023-11-07 2023-08-10 2023-03-01 2022-12-31 2022-09-30
acceptedDate 2024-11-06 07:00:49 2024-08-08 07:06:42 2024-05-08 07:00:48 2023-11-07 07:09:18 2023-11-07 07:09:18 2023-08-10 08:28:14 2023-03-01 08:06:28 2022-12-30 19:00:00 2022-09-29 20:00:00
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 538M 505M 833M 443M 364M 342M 337M 333M 347M
shortTermInvestments 364M 355M 0 0 0 0 0 0 0
cashAndShortTermInvestments 901M 860M 833M 443M 364M 342M 337M 333M 347M
netReceivables 64M 60M 58M 61M 50M 51M 48M 58M 55M
inventory 5M 3M 4M 5M 2M 2M 882 000 943 000 854 000
otherCurrentAssets 36M 34M 31M 10M 16M 19M 0 0 0
totalCurrentAssets 1 006M 957M 926M 529M 416M 395M 386M 392M 404M
propertyPlantEquipmentNet 49M 40M 41M 43M 34M 33M 33M 32M 31M
goodwill 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 2M 410 000 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 2M 410 000 410 000 410 000 0
longTermInvestments 0 0 0 0 0 0 7M 137 000 0
taxAssets 13M 10M 11M 11M 4M 4M 4M 4M 4M
otherNonCurrentAssets 17M 16M 16M 14M 9M 8M 0 7M 7M
totalNonCurrentAssets 79M 67M 68M 68M 48M 45M 45M 44M 41M
otherAssets 0 1 0 0 0 0 0 0 0
totalAssets 1 085M 1 023M 994M 597M 464M 440M 431M 436M 445M
accountPayables 20M 20M 16M 18M 11M 14M 9M 75M 10M
shortTermDebt 49M 1M 1M 1M 2M 3M 2M 2M 2M
taxPayables 962 000 992 000 6M 2M 2M 2M 2M 927 000 1M
deferredRevenue 0 5M 5M 0 2M 3M 5M 6M 11M
otherCurrentLiabilities 196M 163M 133M 120M 82M 73M 69M 51 000 54M
totalCurrentLiabilities 266M 185M 155M 139M 98M 92M 85M 83M 77M
longTermDebt 432M 472M 472M 83M 68M 65M 66M 68M 73M
deferredRevenueNonCurrent 6M 5M 5M 6M 4M 4M 4M 4M 0
deferredTaxLiabilitiesNonCurrent 0 33M -443M 0 0 0 0 0 0
otherNonCurrentLiabilities 3M 2M 445M 978 000 3M 2M 949 000 2M 108 000
totalNonCurrentLiabilities 441M 479M 479M 89M 75M 71M 72M 74M 73M
otherLiabilities 0 1 0 0 0 0 0 0 0
capitalLeaseObligations 42M 35M 35M 36M 31M 29M 29M 30M 29M
totalLiabilities 707M 664M 634M 228M 173M 163M 156M 157M 150M
preferredStock 0 0 0 0 0 0 0 0 0
commonStock 135 000 136 000 135 000 135 000 99 000 98 000 97 000 97 000 96 000
retainedEarnings -772M -781M -769M -745M -290M -292M -278M -261M -236M
accumulatedOtherComprehensiveIncomeLoss -31M -34M -35M -36M 334M 336M 335M 335M 336M
othertotalStockholdersEquity 1 181M 1 174M 1 164M 1 150M 248M 233M 217M 205M 195M
totalStockholdersEquity 378M 359M 360M 369M 292M 277M 274M 279M 295M
totalEquity 378M 359M 360M 369M 292M 277M 274M 279M 295M
totalLiabilitiesAndStockholdersEquity 1 085M 1 023M 994M 597M 464M 440M 431M 436M 445M
minorityInterest 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 1 085M 1 023M 994M 597M 464M 440M 431M 436M 445M
totalInvestments 364M 355M 0 0 0 0 7M 137 000 0
totalDebt 481M 473M 473M 84M 70M 67M 68M 69M 74M
netDebt -57M -32M -360M -359M -294M -275M -269M -263M -273M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol IMCR IMCR IMCR IMCR IMCR IMCR IMCR IMCR IMCR
reportedCurrency USD USD USD GBP GBP GBP GBP GBP GBP
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-06 2024-08-08 2024-05-08 2023-11-07 2023-11-07 2023-08-10 2023-03-01 2022-12-31 2022-11-18
acceptedDate 2024-11-06 07:00:49 2024-08-08 07:06:42 2024-05-08 07:00:48 2023-11-07 07:09:18 2023-11-07 07:09:18 2023-08-10 08:28:14 2023-03-01 08:06:28 2022-12-30 19:00:00 2022-11-18 16:17:11
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
netIncome 9M -12M -24M -26M 2M -14M -17M -25M 6M
depreciationAndAmortization 1M 992 000 1M 121 000 1M 1M 1M 1M 1M
deferredIncomeTax 0 0 0 2M -144 000 151 000 236 000 2M 0
stockBasedCompensation 7M 10M 9M 12M 7M 7M 7M 7M 6M
changeInWorkingCapital -35M 27M 8M -3M 5M 2M 3M 6M 7M
accountsReceivables -2M -3M -6M 0 -1M -6M 0 0 0
inventory 0 0 0 0 0 0 0 0 0
accountsPayables -776 000 4M -2M 0 0 0 0 0 0
otherWorkingCapital -32M 25M 13M -3M 6M 8M 3M 6M 7M
otherNonCashItems 40M 1M 430 000 7M -9M 1M 15M 15M -12M
netCashProvidedByOperatingActivities 21M 23M -5M -9M 5M -2M 9M 6M 8M
investmentsInPropertyPlantAndEquipment -828 000 -331 000 -430 000 -471 000 -2M -768 000 -2M -1M -394 000
acquisitionsNet 0 0 0 0 0 0 0 0 0
purchasesOfInvestments 109 680 -350M 0 0 0 0 0 0 0
salesMaturitiesOfInvestments 0 0 0 0 0 0 0 0 0
otherInvestingActivites -109 680 -350M 0 -9M 4M 3M 2M 2M 597 000
netCashUsedForInvestingActivites -828 000 -350M -430 000 -10M 2M 3M -394 000 332 000 203 000
debtRepayment 0 0 -403M -1M -312 000 -398 000 -407 000 -44M -816 000
commonStockIssued -303 182 303 182 0 0 0 0 0 -117M 117M
commonStockRepurchased 0 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites 198 000 -818 000 -12M 19M 7M 8M 3M 160M 2M
netCashUsedProvidedByFinancingActivities 198 000 -818 000 396M 18M 6M 7M 2M -1M 118M
effectOfForexChangesOnCash 12M -159 000 -800 000 9M 8M -3M -6M -20M 13M
netChangeInCash 33M -328M 390M 79M 22M 5M 5M -15M 139M
cashAtEndOfPeriod 538M 505M 833M 443M 364M 342M 337M 333M 347M
cashAtBeginningOfPeriod 505M 833M 443M 364M 342M 337M 333M 347M 208M
operatingCashFlow 21M 23M -5M -9M 5M -2M 9M 6M 8M
capitalExpenditure -828 000 -331 000 -430 000 -471 000 -2M -768 000 -2M -1M -394 000
freeCashFlow 20M 23M -5M -9M 3M -3M 6M 5M 8M
link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link

Earning call transcript

2024 q2
2024-08-11 ET (fiscal 2024 q2)
2023 q4
2024-02-28 ET (fiscal 2023 q4)
2023 q2
2023-08-10 ET (fiscal 2023 q2)
2022 q4
2023-03-01 ET (fiscal 2022 q4)
2022 q2
2022-08-10 ET (fiscal 2022 q2)

Press-releases

Show financial reports only

2024-11-06 12:00 ET
Immunocore reports third quarter financial results and provides a business update
2024-09-14 07:00 ET
Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer
2024-09-12 20:05 ET
Immunocore to present at the 2024 Cantor Global Healthcare Conference
2024-08-29 11:00 ET
Immunocore announces transition of Chief Financial Officer
2024-08-08 11:00 ET
Immunocore reports second quarter financial results and provides a business update
2024-08-01 11:00 ET
Immunocore to report second quarter 2024 financial results and host call on August 8, 2024
2024-06-18 11:00 ET
Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma
2024-06-01 12:00 ET
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response
2024-05-31 20:05 ET
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024
2024-05-30 20:00 ET
Immunocore to present at the Jefferies Global Healthcare Conference
2024-05-29 11:00 ET
Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma
2024-05-08 11:00 ET
Immunocore reports first quarter financial results and provides a business update
2024-04-24 14:00 ET
Immunocore announces upcoming presentation and posters at ASCO 2024
2024-04-04 20:00 ET
Immunocore to present at upcoming investor conferences
2024-03-05 21:30 ET
Immunocore presented two posters at CROI 2024
2024-03-01 12:00 ET
Immunocore to present at upcoming investor conferences
2024-02-28 12:34 ET
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
2024-02-22 12:00 ET
Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trial
2024-02-21 12:00 ET
Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024
2024-02-01 14:00 ET
DELFI Diagnostics Announces Availability of New Fragmentome-Based Cancer Treatment Monitoring Assay
2024-01-31 04:30 ET
Immunocore Prices Upsized Convertible Senior Notes Offering
2024-01-29 21:05 ET
Immunocore Announces Proposed Convertible Senior Notes Offering
2024-01-05 12:00 ET
Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation
2024-01-03 12:00 ET
Immunocore to present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-11-20 10:08 ET
AGC Biologics to Prepare Late Phase and Commercial Runs for Immunocore
2023-11-07 12:00 ET
Immunocore Reports Third Quarter 2023 Financial Results and Provides Business Update
2023-11-01 20:01 ET
Immunocore announces upcoming poster presentations at SITC Annual Meeting 2023 and SMR Congress 2023
2023-10-30 20:30 ET
Immunocore to present at upcoming investor conferences
2023-10-21 12:45 ET
Immunocore presents three-year overall survival data from the KIMMTRAK Phase 3 trial
2023-10-21 12:45 ET
Immunocore presents three-year overall survival data from the KIMMTRAK Phase 3 trial
2023-10-06 11:01 ET
Immunocore announces upcoming presentation and posters at ESMO 2023
2023-09-11 21:00 ET
Immunocore to present at upcoming investor conferences
2023-09-01 20:00 ET
Immunocore to present at upcoming investor conferences
2023-08-10 11:00 ET
Immunocore Reports Second Quarter 2023 Financial Results and Provides Business Update
2023-08-03 12:00 ET
Immunocore to report second quarter 2023 financial results and host call on August 10, 2023
2023-06-03 11:00 ET
Immunocore presents additional ctDNA data from the KIMMTRAK Phase 3 trial at ASCO
2023-06-01 20:30 ET
Immunocore to present at upcoming investor conferences
2023-05-17 00:01 ET
Ochre Bio Appoints Eliot Forster, Ph.D. as Chairperson of its Board of Directors
2023-05-10 11:00 ET
Immunocore Reports First Quarter 2023 Financial Results and Provides Business Update
2023-05-03 20:30 ET
Immunocore to present at the Bank of America Securities 2023 Health Care Conference
2023-04-18 11:00 ET
Immunocore presents new KIMMTRAK data confirming association between early ctDNA reduction and longer overall survival
2023-04-18 11:00 ET
Grey Wolf Therapeutics Reports Promising Preclinical Data from Research Collaboration with Immunocore in Oral Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023
2023-04-11 11:00 ET
Immunocore to present at the 22nd Annual Needham Virtual Healthcare Conference
2023-03-14 20:30 ET
Immunocore to present four posters at AACR Annual Meeting 2023
2023-03-01 12:00 ET
Immunocore Reports 2022 Financial Results and Provides Business Update
2023-02-28 12:00 ET
Immunocore to present at upcoming investor conferences
2023-02-23 12:00 ET
Immunocore to Report Fourth Quarter and Full Year 2022 Earnings and Host Call on March 1, 2023
2023-02-22 12:00 ET
Immunocore announces initial Phase 1 safety and pharmacodynamic activity data with first soluble TCR therapy for people living with HIV
2023-02-01 12:00 ET
Immunocore to present at upcoming investor conferences
2023-01-09 12:00 ET
Immunocore announces strategic priorities including pipeline expansion for 2023 -2024
2023-01-04 12:00 ET
Immunocore to present at the 41st Annual J.P. Morgan Healthcare Conference
2022-12-15 11:00 ET
Immunocore is awarded the Prix Galien France award for KIMMTRAK
2022-12-14 08:00 ET
Etcembly Announces Breakthrough in Optimising TCR Assets
2022-12-08 11:30 ET
Immunocore presents ovarian cancer expansion data for ImmTAC® candidate IMC-C103C targeting MAGE-A4
2022-12-02 12:30 ET
Immunocore and Gadeta Announce Agreement to Develop First Gamma Delta (γδ) TCR ImmTAC for Solid Tumors
2022-11-23 12:00 ET
Immunocore to present at the 5th Annual Evercore ISI HealthCONx Conference
2022-11-11 14:00 ET
Immunocore presents new biomarker analysis for KIMMTRAK (tebentafusp-tebn) in metastatic uveal melanoma at the SITC 2022 Annual Meeting
2022-11-10 12:00 ET
Immunocore to present at the Jefferies London Healthcare Conference
2022-11-09 13:00 ET
Medison Pharma Announces Expansion of the Multi-Territorial Agreement with Immunocore into Latin America
2022-11-09 12:00 ET
Immunocore Reports Third Quarter 2022 Financial Results and Provides Business Update
2022-09-09 14:00 ET
Immunocore presents promising initial Phase 1 data for first off-the-shelf TCR therapy targeting PRAME at the ESMO 2022 Congress
2022-09-09 14:00 ET
Immunocore presents promising initial Phase 1 data for first off-the-shelf TCR therapy targeting PRAME at the ESMO 2022 Congress
2022-08-10 11:00 ET
Immunocore Reports Second Quarter 2022 Financial Results and Provides Business Update
2022-08-03 11:00 ET
Immunocore to Report Second Quarter 2022 Earnings and Host Call on August 10, 2022
2022-08-01 11:00 ET
Immunocore announces upcoming oral presentation of initial Phase 1 data of ImmTAC® candidate IMC-F106C targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022
2022-07-18 11:00 ET
Immunocore Announces $140 Million Private Placement Financing
2022-07-11 11:00 ET
Immunocore announces dosing of first patient with ImmTAV® bispecific for HIV
2022-06-25 08:00 ET
Immunocore announces the presentation of initial data from the Phase 1 ImmTAV® trial for chronic Hepatitis B at the EASL International Liver Congress™
2022-06-09 11:45 ET
Immunocore Appoints Siddharth Kaul to its Board of Directors
2022-06-08 15:43 ET
Medison Pharma Announces the Approvals by Health Canada and Therapeutics Goods Administration of KIMMTRAK® (tebentafusp) for the Treatment of Unresectable or Metastatic Uveal Melanoma
2022-06-08 11:00 ET
The UK Medicines and Healthcare products Regulatory Agency (MHRA), Australian Therapeutic Goods Administration (TGA) and Health Canada approve KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma
2022-06-06 11:00 ET
Immunocore presents new data on KIMMTRAK (tebentafusp-tebn) in metastatic cutaneous (mCM) and uveal melanoma (mUM) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
2022-06-03 11:00 ET
Immunocore announces clinical trial collaboration with Sanofi to evaluate Sanofi’s product candidate SAR444245, non-alpha IL-2, in combination with KIMMTRAK® in patients with metastatic cutaneous melanoma
2022-06-01 20:30 ET
Immunocore to present at upcoming investor conferences
2022-05-26 22:00 ET
Immunocore announces upcoming presentations at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
2022-05-23 11:24 ET
Medison Pharma Announces Extension of Multi-territorial Agreement with Immunocore and Expansion into Australia and New Zealand
2022-05-11 11:00 ET
Immunocore Reports First Quarter 2022 Financial Results and Provides Business Update
2022-04-07 11:00 ET
Immunocore to present at the 21st Annual Needham Healthcare Conference
2022-04-04 11:00 ET
European Commission Approves KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma
2022-03-09 22:30 ET
Immunocore to present at Oppenheimer’s 32nd Annual Healthcare Conference
2022-03-03 12:00 ET
Immunocore Reports Full Year 2021 Financial Results and Provides Business Update
2022-02-25 07:00 ET
Immunocore receives positive CHMP opinion for KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma
2022-02-15 12:00 ET
ArriVent Biopharma Appoints Bahija Jallal to its Board of Directors
2022-02-11 12:00 ET
Immunocore to present at the SVB Leerink Global Healthcare Conference
2022-01-26 12:00 ET
Immunocore announces FDA approval of KIMMTRAK® (tebentafusp-tebn) for the treatment of unresectable or metastatic uveal melanoma
2022-01-06 12:00 ET
Immunocore to present at the 40th Annual J.P. Morgan Healthcare Conference
2021-12-06 12:00 ET
Immunocore announces initial Phase 1 data of ImmTAC® candidate IMC-C103C targeting MAGE-A4
2021-11-11 12:00 ET
Immunocore to present at the Jefferies London Healthcare Conference
2021-11-10 12:00 ET
Immunocore Reports Third Quarter 2021 Financial Results and Provides Business Update
2021-11-09 13:01 ET
Immunocore presents new data on tebentafusp in metastatic cutaneous melanoma (mCM) and uveal melanoma (mUM) at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
2021-10-18 11:30 ET
Immunocore and Medison Pharma Partner for Future Commercialization of Tebentafusp in Canada, Central Eastern Europe, and Israel
2021-09-22 22:00 ET
Immunocore announces publication of phase 3 data comparing tebentafusp with investigator’s choice in The New England Journal of Medicine
2021-09-21 10:30 ET
Dr. Carolin Barth Joins MiroBio as CEO to Lead Precision Immunology Company Focused on Checkpoint Agonist Antibodies
2021-09-21 10:30 ET
Dr. Carolin Barth Joins MiroBio as CEO to Lead Precision Immunology Company Focused on Checkpoint Agonist Antibodies
2021-09-20 11:00 ET
Immunocore presents data at the European Society for Medical Oncology (ESMO) Congress 2021 demonstrating a reduction in circulating tumor DNA (ctDNA) while on tebentafusp is associated with overall survival in the Phase 2 clinical trial
2021-09-15 12:00 ET
iECURE Appoints Brian Di Donato to Board of Directors
2021-09-13 20:30 ET
Immunocore Announces Upcoming Presentations at the European Society for Medical Oncology (ESMO) Congress 2021
2021-09-10 11:00 ET
Immunocore to present at upcoming investor conferences
2021-09-08 11:00 ET
Immunocore Announces UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) Accepts Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma
2021-08-24 11:00 ET
Immunocore Announces that U.S. Food and Drug Administration and European Medicines Agency accept Biologics License Application and Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma
2021-08-11 11:00 ET
Immunocore Reports Second Quarter 2021 Financial Results and Provides Business Update
2021-06-04 13:05 ET
Immunocore presents clinical data further characterizing the overall survival benefit of tebentafusp in metastatic uveal melanoma at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
2021-05-27 20:30 ET
Immunocore to present at upcoming investor conferences
2021-05-27 20:30 ET
Immunocore to present at upcoming investor conferences
2021-05-18 20:10 ET
Immunocore announces dosing of first patient with ImmTAV® bispecific molecule for chronic Hepatitis B
2021-05-12 11:00 ET
Immunocore Reports First Quarter 2021 Financial Results
2021-05-12 11:00 ET
Immunocore Reports First Quarter 2021 Financial Results
2021-04-28 20:30 ET
Immunocore Announces Upcoming Presentations at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
2021-04-16 10:00 ET
IDEAYA Reports Darovasertib (IDE196) Monotherapy Overall Survival Data and Observes Early Partial Responses in Binimetinib Combination in Metastatic Uveal Melanoma
2021-04-12 20:30 ET
Immunocore presents phase 3 data comparing tebentafusp with investigator’s choice in the clinical trial plenary session at the American Association for Cancer Research 2021 Annual Meeting
2021-04-12 20:30 ET
Immunocore presents phase 3 data comparing tebentafusp with investigator’s choice in the clinical trial plenary session at the American Association for Cancer Research 2021 Annual Meeting
2021-03-25 11:00 ET
Immunocore Provides Business Update and Reports Full Year 2020 Financial Results
2021-03-11 00:00 ET
Immunocore Announces Upcoming Presentations at the American Association for Cancer Research (AACR) 2021 Annual Meeting
2021-02-19 12:00 ET
Immunocore’s tebentafusp granted Breakthrough Therapy Designation for unresectable or metastatic uveal melanoma from FDA
2021-02-16 12:00 ET
Immunocore announces key appointments to management and Board
2021-02-16 12:00 ET
Immunocore announces key appointments to management and Board
2021-02-10 09:00 ET
Citi Appointed as Depositary Bank for Immunocore Holdings plc’s ADR Programme
2021-02-09 21:05 ET
Immunocore Announces Closing of $312.1 Million Aggregate Financing, Consisting of $297.1 Million Initial Public Offering, Full Exercise of Option to Purchase Additional ADSs and $15.0 Million Concurrent Private Placement
2021-02-09 21:05 ET
Immunocore Announces Closing of $312.1 Million Aggregate Financing, Consisting of $297.1 Million Initial Public Offering, Full Exercise of Option to Purchase Additional ADSs and $15.0 Million Concurrent Private Placement
2021-02-05 03:07 ET
Immunocore Announces Pricing of Upsized Initial Public Offering
2021-02-05 03:07 ET
Immunocore Announces Pricing of Upsized Initial Public Offering

SEC forms

Show financial reports only

SEC form 8
2025-02-26 00:00 ET
Immunocore Holdings plc reported for 2024 q4
SEC form 8
2025-02-26 00:00 ET
Immunocore Holdings plc published news for 2024 q4
SEC form 10
2025-02-26 00:00 ET
Immunocore Holdings plc published news for 2024 q4
SEC form 8
2025-01-10 00:00 ET
Immunocore Holdings plc published news for 2024 q4
SEC form 8
2025-01-10 00:00 ET
Immunocore Holdings plc published news for 2024 q4
SEC form 8
2025-01-10 00:00 ET
Immunocore Holdings plc published news for 2024 q4
SEC form 8
2025-01-10 00:00 ET
Immunocore Holdings plc published news for 2024 q4
SEC form 8
2024-11-06 07:22 ET
Immunocore Holdings plc reported for 2024 q3
SEC form 8
2024-11-06 07:22 ET
Immunocore Holdings plc published news for 2024 q3
SEC form 10
2024-11-06 07:00 ET
Immunocore Holdings plc reported for 2024 q3
SEC form 8
2024-08-08 07:21 ET
Immunocore Holdings plc published news for 2024 q2
SEC form 8
2024-08-08 07:21 ET
Immunocore Holdings plc reported for 2024 q2
SEC form 10
2024-08-08 07:06 ET
Immunocore Holdings plc reported for 2024 q2
SEC form 10
2024-08-08 00:00 ET
Immunocore Holdings plc reported for 2024 q2
SEC form 8
2024-05-08 07:13 ET
Immunocore Holdings plc published news for 2024 q1
SEC form 8
2024-05-08 07:13 ET
Immunocore Holdings plc reported for 2024 q1
SEC form 10
2024-05-08 07:00 ET
Immunocore Holdings plc reported for 2024 q1
SEC form 10
2024-05-08 00:00 ET
Immunocore Holdings plc reported for 2024 q1
SEC form 8
2024-02-28 16:19 ET
Immunocore Holdings plc published news for 2023 q4
SEC form 8
2024-02-28 16:19 ET
Immunocore Holdings plc reported for 2023 q4
SEC form 8
2024-02-28 16:19 ET
Immunocore Holdings plc published news for 2023 q4
SEC form 10
2024-02-28 07:33 ET
Immunocore Holdings plc reported for 2023 q4
SEC form 10
2024-02-28 00:00 ET
Immunocore Holdings plc reported for 2023 q4
SEC form 8
2024-01-29 00:00 ET
Immunocore Holdings plc published news for 2023 q4
SEC form 8
2024-01-29 00:00 ET
Immunocore Holdings plc published news for 2023 q4
SEC form 8
2024-01-29 00:00 ET
Immunocore Holdings plc published news for 2023 q4
SEC form 8
2024-01-05 00:00 ET
Immunocore Holdings plc published news for 2023 q4
SEC form 8
2024-01-05 00:00 ET
Immunocore Holdings plc published news for 2023 q4
SEC form 8
2024-01-05 00:00 ET
Immunocore Holdings plc published news for 2023 q4
SEC form 8
2024-01-05 00:00 ET
Immunocore Holdings plc published news for 2023 q4
SEC form 6
2023-11-07 07:09 ET
Immunocore Holdings plc reported for 2023 q3
SEC form 6
2023-08-10 08:28 ET
Immunocore Holdings plc reported for 2023 q2
SEC form 6
2023-07-14 16:21 ET
Immunocore Holdings plc published news for 2023 q2
SEC form 6
2023-06-05 09:20 ET
Immunocore Holdings plc published news for 2023 q1
SEC form 6
2023-04-18 16:15 ET
Immunocore Holdings plc published news for 2023 q1
SEC form 6
2023-04-18 16:13 ET
Immunocore Holdings plc published news for 2023 q1
SEC form 6
2023-03-10 07:00 ET
Immunocore Holdings plc published news for 2022 q4
SEC form 6
2023-03-02 08:15 ET
Immunocore Holdings plc published news for 2022 q4
SEC form 6
2023-03-01 09:13 ET
Immunocore Holdings plc reported for 2022 q4
SEC form 6
2023-03-01 08:06 ET
Immunocore Holdings plc published news for 2022 q4
SEC form 6
2023-02-22 17:25 ET
Immunocore Holdings plc published news for 2022 q4
SEC form 6
2023-01-11 16:18 ET
Immunocore Holdings plc published news for 2022 q4
SEC form 6
2023-01-09 16:43 ET
Immunocore Holdings plc published news for 2022 q4
SEC form 6
2022-12-08 16:59 ET
Immunocore Holdings plc published news for 2022 q3
SEC form 6
2022-12-02 17:08 ET
Immunocore Holdings plc published news for 2022 q3
SEC form 6
2022-11-18 16:17 ET
Immunocore Holdings plc reported for 2022 q3
SEC form 6
2022-11-14 07:59 ET
Immunocore Holdings plc published news for 2022 q3
SEC form 6
2022-11-09 07:15 ET
Immunocore Holdings plc published news for 2022 q3
SEC form 6
2022-09-30 16:24 ET
Immunocore Holdings plc published news for 2022 q2
SEC form 6
2022-09-09 16:29 ET
Immunocore Holdings plc published news for 2022 q2
SEC form 6
2022-09-09 12:33 ET
Immunocore Holdings plc published news for 2022 q2
SEC form 6
2022-08-10 08:00 ET
Immunocore Holdings plc published news for 2022 q2
SEC form 6
2022-07-20 16:06 ET
Immunocore Holdings plc published news for 2022 q2
SEC form 6
2022-07-11 16:05 ET
Immunocore Holdings plc published news for 2022 q2
SEC form 6
2022-06-27 16:05 ET
Immunocore Holdings plc published news for 2022 q1
SEC form 6
2022-06-09 16:12 ET
Immunocore Holdings plc published news for 2022 q1
SEC form 6
2022-06-08 16:06 ET
Immunocore Holdings plc published news for 2022 q1
SEC form 6
2022-06-06 16:21 ET
Immunocore Holdings plc published news for 2022 q1
SEC form 6
2022-06-03 16:05 ET
Immunocore Holdings plc published news for 2022 q1
SEC form 6
2022-05-12 16:25 ET
Immunocore Holdings plc published news for 2022 q1
SEC form 6
2022-05-11 07:08 ET
Immunocore Holdings plc published news for 2022 q1
SEC form 6
2022-04-14 16:11 ET
Immunocore Holdings plc published news for 2022 q1
SEC form 6
2022-04-04 16:06 ET
Immunocore Holdings plc published news for 2022 q1
SEC form 6
2022-03-03 07:09 ET
Immunocore Holdings plc published news for 2021 q4
SEC form 6
2022-03-03 07:01 ET
Immunocore Holdings plc published news for 2021 q4
SEC form 6
2022-01-26 16:29 ET
Immunocore Holdings plc published news for 2021 q4
SEC form 6
2021-12-07 16:10 ET
Immunocore Holdings plc published news for 2021 q3
SEC form 6
2021-11-10 07:01 ET
Immunocore Holdings plc published news for 2021 q3
SEC form 6
2021-08-24 16:33 ET
Immunocore Holdings plc published news for 2021 q2
SEC form 6
2021-08-11 07:00 ET
Immunocore Holdings plc published news for 2021 q2
SEC form 6
2021-05-12 07:00 ET
Immunocore Holdings plc published news for 2021 q1
SEC form 6
2021-03-25 07:01 ET
Immunocore Holdings plc published news for 2020 q4